Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Lupus Nephritis · IgG4-related Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tongji Hospital, Wuhan, Hubei, China
Contact: Study coordinator (Lingli Dong, MD) · tjhdongll@163.com · 02783665519
Contact: Study coordinator (Ziwei Hu) · 836048368@qq.com · 02783665518

Study leads

Lingli Dong, MD
Principal Investigator
Tongji Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

Lupus Nephritis · IgG4-related Disease

Abroad (travel likely)RecruitingEARLY_PHASE1

Wuhan, China

Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

Lupus Nephritis · ANCA Associated Vasculitis

Abroad (travel likely)Recruiting

Wuhan, China

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

Lupus Nephritis (LN)

Abroad (travel likely)RecruitingPHASE1

Rochester, United States · Houston, United States

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erthematosus (SLE) · Lupus Nephritis (LN) · Extra-renal Lupus (ERL)

Abroad (travel likely)RecruitingPHASE1

Brisbane, Australia